KOSDAQBiotech & Pharma950160

Kolon TissueGene

₩16,200▼ 1.58%2026-10-02 close

Market Cap

₩1.4T

Turnover

₩6.7B

Volume

420,000 shares

Shares out.

85M

PER

—

PBR

—

EPS

-₩2,011

Dividend Yield

—

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Prices as of the 2026-10-02 close

Report overview

Two Things to Watch: Trial Re-analysis and Capital Structure

After the first U.S. Phase 3 trial of TG-C missed its co-primary endpoints, the company is staking everything on explaining the placebo response and on the second Phase 3 readout now pushed to December, while its financials show only a few billion won of revenue and a bottom line dominated by derivative valuation swings.

1
The first U.S. Phase 3 of TG-C failed to show statistical significance versus placebo on its co-primary endpoints, pain (VAS) and function (WOMAC), at 12 months.
2
Management says efficacy was in line with prior trials and blames an unusually strong placebo response; the second Phase 3 topline has been delayed from October to December.
3
2025 revenue was 4.92 billion won with a 21.3 billion won operating loss, marking a fourth straight year of operating losses around 20 billion won.
4
Valuation of convertible bond derivatives dominates the bottom line: the 2025 net loss attributable to owners was 183.7 billion won, while 2Q26 flipped to a 45.4 billion won net profit.
5
Equity of 60.6 billion won against 340.3 billion won of liabilities at end-2025 (debt ratio 561.6%) shows how fast the capital structure changed, with the CB conversion window opening on September 26, 2026.

Business structure

Kolon TissueGene is a U.S.-incorporated member of the Kolon group whose shares trade on Korea's KOSDAQ market as Korean Depositary Receipts, which sets it apart from an ordinary listed company. It is a U.S. entity but is not listed in the United States, and five KDRs have been issued per common share.

In substance the business is a single-pipeline R&D company holding global rights, including the U.S. and Europe, to the osteoarthritis cell and gene therapy TG-C, formerly known as Invossa.

Kolon Life Science holds Asian rights to Invossa, while Kolon TissueGene holds global rights covering the United States and Europe. TG-C combines normal chondrocytes with cells transduced to express TGF-beta1.

With no commercial product yet, revenue stays at a few billion won a year, and most spending goes to clinical and R&D costs plus personnel.

During the 2019 component controversy, the second component was found to be kidney-derived rather than the chondrocytes described in the filing, which also put the U.S. trial on hold for a time, and the U.S. Phase 3 resumed in 2021 while share trading restarted in October 2022.

On governance, a February 2026 criminal ruling confirmed the acquittal of the owner family, removing much of the legal overhang, and Kolon group vice chairman Lee Kyu-ho joined the board at the March annual general meeting.

Funding has come not from operating cash flow but from equity injections by largest shareholder Kolon Corp and mezzanine issuance to institutions.

Earnings trend

Quarterly revenue · Operating profit

₩1.3B-₩5.3B25Q2₩1.6B-₩3.4B25Q3₩800M-₩7.5B25Q4₩1.3B-₩5B26Q1₩700M-₩6.5B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩9.9B-₩17.1B2022₩3.9B-₩21.3B2023₩5B-₩21.9B2024₩4.9B-₩21.3B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩1.3B	-₩5.3B	−411.8%
2025Q3	₩1.6B	-₩3.4B	−208.4%
2025Q4	₩800M	-₩7.5B	−950.1%
2026Q1	₩1.3B	-₩5B	−381.5%
2026Q2	₩700M	-₩6.5B	−869.2%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩9.9B	-₩17.1B	-₩11.7B	−172.4%	−11.9%	20.1%
2023	₩3.9B	-₩21.3B	-₩17.9B	−553.3%	−14.8%	17.4%
2024	₩5B	-₩21.9B	-₩33.6B	−433.6%	−25.0%	52.4%
2025	₩4.9B	-₩21.3B	-₩183.7B	−432.7%	−303.2%	561.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

2025 revenue of 4.92 billion won was little changed from 5.05 billion won in 2024 and above the 3.85 billion won of 2023, but only about half the 9.93 billion won of 2022.

Operating losses ran 17.1 billion won in 2022, 21.3 billion won in 2023, 21.9 billion won in 2024 and 21.3 billion won in 2025, a fourth consecutive year near 20 billion won, and operating margins of -432.7% in 2025, -433.6% in 2024 and -553.3% in 2023 show that revenue simply cannot cover the cost base.

The bigger issue is the swing in net income.

The 2025 net loss attributable to owners reached 183.72 billion won, more than eight times the operating loss, as the company recognized valuation losses on the conversion and redemption options embedded in its convertible bonds; it disclosed a cumulative loss balance of 94.85 billion won as of March 31, 2026 and described it as a non-cash accounting loss.

Quarterly figures moved the same way, with net losses attributable to owners of 117.78 billion won in 4Q25 and 92.49 billion won in 1Q26.

In 2Q26 the bottom line flipped to a net profit of 45.40 billion won even though the quarter still carried a 6.51 billion won operating loss, meaning the sign of net income is set by derivative valuation rather than by the business.

The balance sheet changed character within a year: equity fell from 134.66 billion won at end-2024 to 60.59 billion won at end-2025 while liabilities rose from 70.50 billion won to 340.30 billion won, lifting the debt-to-equity ratio from 52.4% to 561.6%.

Operating cash flow was negative every year, at -28.12 billion won in 2022, -25.06 billion won in 2023, -20.34 billion won in 2024 and -22.91 billion won in 2025. Quarterly revenue slipped from 1.31 billion won in 1Q26 to 0.75 billion won in 2Q26, underscoring how small and volatile the top line remains.

Industry analysis

Osteoarthritis is a large treatment market with an empty slot at the disease-modifying end. Research houses put the global osteoarthritis treatment market at roughly 40 to 60 billion dollars with growth projected around 7% a year. No disease-modifying osteoarthritis drug, or DMOAD, has yet been approved by the U.S.

Food and Drug Administration, which is why global pharma and biotech firms are competing to develop one.

Standard care for knee osteoarthritis, painkillers, steroid injections and joint replacement, only eases pain and inflammation, whereas a DMOAD aims to slow disease progression itself through cartilage regeneration and structural improvement.

Even so, over some two decades global drugmakers repeatedly failed to commercialize candidates because they could not demonstrate structural improvement radiographically or could not secure clinical significance. The domestic field is also taking shape.

Korean challengers in DMOAD include Medipost, Biosolution, Kangstem Biotech, Ensol Biosciences and Yipscell alongside Kolon TissueGene, and Medipost completed first patient enrollment and dosing in the U.S. Phase 3 of its cord blood-derived stem cell therapy Cartistem in July 2026.

Kolon TissueGene had the most advanced timeline, but missing the primary endpoints in the first Phase 3 has pushed the premise of its first-in-the-world positioning back into re-validation, and the placebo response problem specific to this disease has emerged as a shared risk across the field.

Outlook

The clearest scheduled event is the second U.S. Phase 3 readout. The company said it pushed the second Phase 3 topline from October to December so that it can also pin down why the placebo effect was unusually strong in the first trial and complete an integrated analysis.

Chief executive Jeon Seung-ho said additional analysis of the first trial will be done with multiple global contract research organizations and that the second trial's topline analysis will be run independently by an external CRO.

He cited the rigor of that verification as the reason for the delay and said talks with the FDA would follow once December results are in hand. The company has left open the possibility of an additional trial, which is expected to push out the commercialization timeline it had planned for the second half of 2028.

The regulatory path still carries variables. Management noted a recent shift under which approval might be possible on a single trial, unlike the standing requirement for statistical significance in two trials, while stressing that whether it applies is uncertain and that the second trial's outcome cannot be prejudged.

On pipeline, it said it is also reviewing the in-licensing of additional drug candidates.

Funding still depends on external sources: a March 2026 board resolution approved a 60 billion won third-party share placement to largest shareholder Kolon Corp, with 30 billion won each planned as working capital this year and next (per March 2026 press reports).

In short, the December data, subsequent FDA discussions and the handling of outstanding mezzanine securities will define the facts over the coming year.

Valuation

PER

—

PBR

—

ROE

-115.6%

EPS

-₩2,011

BPS

—

Dividend per share

—

With losses on the books there is no meaningful earnings multiple, and the company pays no dividend. The market price reflects expectations about TG-C's clinical re-analysis and regulatory path rather than current results, and the shares trade at a substantial premium to net assets.

That comparison also embeds an accounting effect: equity shrank during 2025 as convertible bond derivatives were recognized as sizable liabilities.

For reference, Korea Investment & Securities analyst Wi Hae-joo cut the rating from Buy to Neutral in a July 21, 2026 report, saying that a successful second trial would keep a filing and a 2028 launch possible but that the share price already reflected much of the risk-adjusted net present value (that is the brokerage's view, not ours).

In addition, convertible and exchangeable bonds issued on Kolon TissueGene shares totaled 239 billion won, of which 193.7 billion won had not been converted or exchanged as of July 29, 2026, comprising 138.5 billion won of CBs and 55.2 billion won of EBs, so share count and total equity can both move depending on how those are converted or redeemed.

When looking at asset- or earnings-based metrics, therefore, it is more practical to review the derivative liabilities and potential share count alongside them.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Efficacy readings held at prior trial levels

In the first Phase 3, the co-primary endpoints VAS and WOMAC missed significance versus placebo at 12 months, yet the TG-C arm showed a 38.7-point VAS reduction and a 27.61-point WOMAC reduction, similar to or better than the earlier U.S. Phase 2 and Korean Phase 3.

The placebo arm improved by 39.2 points on VAS and 26.54 on WOMAC, erasing the gap between arms. The company stressed that efficacy itself was consistent with prior trials and attributed the outcome to a larger-than-expected placebo response.

If the driver is the control arm rather than lost efficacy, the bull case argues room remains to refine trial design.

A second Phase 3 and independent verification remain

The U.S. Phase 3 program was split into two trials with 1,066 patients in total. The second U.S. Phase 3, study 12301, has been running, and analysts noted that a possible FDA filing still hinges on its outcome. The company said the second trial's topline analysis will be performed independently by an external CRO.

Because the results and the verification method will be disclosed together, the volume of verifiable information rises sharply in December.

An empty market and a track record of parent funding

No disease-modifying osteoarthritis drug has been approved by the FDA, so a successful development would land in an unoccupied market. Research houses size the global osteoarthritis treatment market at roughly 40 to 60 billion dollars.

Kolon Corp has supplied funds to Kolon TissueGene every year since 2021, and the March 2026 resolution extended that to a fifth consecutive year of controlling-shareholder support. It is a matter of record that parent funding has filled the gap left by the absence of internally generated cash before commercialization.

Bear factors

The fact of missed co-primary endpoints

On July 20 the verdict on the Phase 3 was that the co-primary endpoints were not met. In a July 26 letter on the corporate website, co-chief executives Noh Moon-jong and Jeon Seung-ho apologized for the disappointment caused by the first readout and said they take the result very seriously.

The FDA's standing requirement is statistical significance in two trials for approval. Whatever the root-cause analysis concludes, one failed trial stays on the record at the regulatory gate.

Delays and a pushed-back commercialization date

The second Phase 3 topline slipped from October to December, and the company noted that even December is a tight schedule. With an additional trial now possible, the commercialization timeline once planned for the second half of 2028 also looks set to slip.

As of January 2026 the company had guided to ending follow-up in March and reporting primary endpoints in July. The longer development runs, the longer clinical and operating costs must be funded.

Mezzanine redemption and dilution overhang

The 122.5 billion won convertible bond issued in September 2025 carries a conversion price of 218,090 won per common share, a conversion window opening September 26, 2026, and put rights exercisable every three months from two years after issuance.

The CB includes a refixing clause and, from next year, holders can demand principal repayment, so a slow share price recovery could bring early principal redemption. The refixing floor, however, is capped at 85% of the initial conversion price.

Commentators have flagged that CB conversion combined with new placement shares raises concerns about per-share dilution from an expanding share count.

Risk factors

Clinical and regulatory risk

With a single pipeline, the December second Phase 3 result effectively determines the premise of the company's value. Whether a policy shift allowing approval on one trial would apply is uncertain, and the company itself will not prejudge the second trial's outcome.

The repeated commercialization failures of global drugmakers over some two decades, unable to prove structural improvement, illustrate how hard this indication is. If an additional trial becomes necessary, both development time and cost increase.

Financial and funding risk

On confirmed figures, 2025 operating cash flow was -22.91 billion won, a fourth straight year of net outflows in the 20 billion won range, while equity fell to 60.59 billion won and liabilities rose to 340.30 billion won for a 561.6% debt-to-equity ratio.

With no commercial revenue, working capital depends on external funding, and industry observers read this repeated fundraising as runway management typical of a late-stage clinical biotech. Should funding terms worsen or put option claims cluster, headroom in the funding plan narrows.

Accounting volatility and credibility risk

Because net income is driven by derivative valuation, the direction of quarterly results can diverge from business reality.

The company explained that a rising share price lifted the fair value of the CB derivatives, creating a non-cash accounting loss, and that conversion into shares would move the liability into equity with a balance sheet improvement effect.

Conversely, a falling share price books valuation gains, so a net profit alone cannot be read as business improvement. The past component controversy and the resulting hold on the U.S. trial, combined with the market concern that grew after the topline release, leave communication credibility itself as a variable.

What to watch next

September 26, 2026
The conversion window opens for the 122.5 billion won convertible bond issued in September 2025. Whether and how much is converted will depend on the share price relative to the conversion price, and both share count and derivative liability recognition can shift afterward.
During November 2026
The 3Q26 quarterly report. Check the quarterly operating loss, operating cash flow, equity and liabilities, and the direction of derivative valuation gains or losses to separate business-driven swings from valuation-driven ones.
December 2026
The second U.S. Phase 3 topline is scheduled for release together with the integrated analysis of the first trial. Key items to verify are whether co-primary endpoints are met, the explanation for the placebo response, and any imaging data on structural improvement.
After December 2026
The company says it will proceed with FDA discussions once December results are available. Those talks will determine the filing timing, whether an additional trial is required, and how the commercialization schedule is reset.
Around March 2027
The FY2026 annual report. This is the point to check the full-year operating loss and cash burn, changes in equity and the debt ratio, and whether the additional pipeline in-licensing the company said it was reviewing has actually advanced.

Overall view

Kolon TissueGene is effectively a single-pipeline company built around TG-C, and the current phase begins with the first U.S. Phase 3 missing its co-primary endpoints in July 2026.

Management maintains that efficacy was consistent with prior trials and that a larger-than-expected placebo response affected the outcome, and the second Phase 3 topline has been moved from October to December so it can be disclosed alongside the analysis of the first trial.

Financially, 2025 revenue of 4.92 billion won against a 21.3 billion won operating loss extends a fourth straight year of operating losses near 20 billion won, while the extreme swing from a 183.72 billion won net loss attributable to owners to a 45.40 billion won net profit in 2Q26 stems from valuation of convertible bond derivatives.

Equity of 60.59 billion won versus liabilities of 340.30 billion won at end-2025, a 561.6% debt ratio, and operating cash flow of -22.91 billion won lay bare a pre-commercial funding structure.

The bull case rests on efficacy readings holding up and on the second trial plus independent verification still to come; the bear case rests on one confirmed failure at the regulatory gate, the schedule slippage, and simultaneous mezzanine redemption and dilution overhang.

The order of verification is therefore the conversion window opening on September 26, the third-quarter report in November, and the December second Phase 3 result followed by FDA discussions. This material is for information purposes only and contains no buy or sell recommendation.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.